Baxter International has entered into a strategic partnership with ScinoPharm Taiwan, a Taiwan-based provider of process research and development and active pharmaceutical ingredient (API) manufacturing services, to develop, manufacture, and commercialize five injectable generic anti-cancer drugs for treating several cancers, including lung cancer, multiple myeloma, and breast cancer as well as an injectable medication to treat the nausea and vomiting side effects of chemotherapy.

Under the partnership, Baxter and ScinoPharm will collaborate on product development and manufacturing. ScinoPharm will provide APIs for the initial five generic injectables, and Baxter and ScinoPharm will share manufacturing responsibilities, with the majority of the molecules to be manufactured at Baxter’s facility in Halle, Germany.

Baxter will hold commercialization rights, with products included in the arrangement expected to launch beginning in 2020. The arrangement also provides Baxter the option to partner with ScinoPharm on as many as 15 additional injectable molecules.

Current branded sales of the initial five products included in this partnership, which were not disclosed, total more than $4 billion annually, according to Baxter. These products will join Baxter’s existing portfolio of generic injectable medications, which includes difficult-to-manufacture oncology drugs and a portfolio of standard-dose, ready-to-use premixed injectable products such as anti-infectives, analgesics, and critical care medicines.

Source: Baxter International